Congratulations to Prof. Denis Migliorini, M.D., on his publication in “Nature Biomedical Engineering”, in which he describes novel therapeutic options in the fight against brain tumors. The ISREC Foundation is proud to support his Brain Tumor Immunology Chair and his research, which offers hope to many patients.

For more information: Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence | Nature Biomedical Engineering

Congratulations to Anaïs Golliet, winner of the ISREC Foundation’s Pierre-François Leyvraz Award 2025 for interprofessionality in oncology.

Anaïs Golliet receives this award for her project entitled “Analysis of the implementation of consultations by nursing professionals prior to the signing of a consent form for participation in an oncological clinical trial”.

This analysis of the implantation has been realized by Anaïs Golliet and Nour Al Akkachy, both of them from Masters in sciences infirmières at the IUFRS – Institut universitaire de formation et de recherche en soins à l’UNIL. Their work addresses the fundamental issues of information and informed consent in clinical trials, and stands out for its feasibility, clinical relevance and expected benefits for a large number of patients. It is part of a national initiative to promote autonomous consultations by nursing professionals.

This award was created by the ISREC Foundation in 2019 to honor the commitment of Professor Pierre-François Leyvraz, former Director General of the CHUV, to its Scientific Board. It recognizes projects carried out during training that promote the development of interprofessionality in the field of oncology.

Congratulations to Anaïs Golliet on this well-deserved recognition!

Once again, the SUR-SRP “Summer Research” program (July 3 to August 28), organized by the UNIL and the EPFL and supported by the ISREC Foundation, was a huge success. The students were thrilled to discover AGORA. We hope that this once-in-a-lifetime experience will open up new horizons for them.

The ISREC Foundation is pleased to announce the winners of the TANDEM 2025 call for projects, which this year focusses on digital pathology in cancer research. 

Six interdisciplinary teams were selected based on the scientific quality of their projects and a strong potential for clinical translation. Three are based in the French-speaking part of Switzerland, two in the German-speaking area and one in Ticino.

These projects, jointly led by a clinician and a basic research scientist, showcase the diversity of collaborations taking place across Switzerland and are in line with our goal of bringing science closer to patients.

Find out more about the winning teams and their projects here

26th edition of this race, organized by Team Girard.

Since 1998, the Club Team Girard, including owners, riders and fans of vintage motorcycles, organizes a yearly hill climb event for old-timers and donates part of the profits to the ISREC Foundation. 

For more information (in French) Team-Girard rétrospective de la course de Corcelles-le-Jorat

Currently director of ISREC@EPFL, Elisa was the holder of the ISREC Foundation’s professorship in translational oncology from 2014 to 2020.

This election is recognition of her commitment to excellence in biomedical research.

For more information: Elisa Oricchio and Andrew Oates elected EMBO Members – EPFL

Voici la photo à utiliser, je vous laisse la travailler pour que le format joue avec notre site.

Scientists at the University of Geneva and the CHUV (Lausanne University Hospital) have discovered that a certain set of immune cells, long considered merely auxiliary, can be reprogrammed to directly attack cancer cells. This promising breakthrough paves the way for faster and more effective personalized treatments, including for pediatric cancers.

The ISREC Foundation is proud to fund this important project, conducted jointly by Prof. Camilla Jandus, Francesco Ceppi – MD PD MERc, and Prof. George Coukos at the University of Geneva and the CHUV, the aim being to strengthen immunotherapies in the fight against cancer.

Our commitment to supporting translational research, which bridges the gap between the lab and the patient’s bedside, is fully reflected in this work.

Congratulations to the teams involved in this project, and many thanks to all who contribute to these developments! For more information: Cancer: «forgotten» cells go on the offensive – Medias – UNIGE

For over six decades, we have pursued a single goal: the advancement of cancer research for the benefit of patients.

By supporting the most innovative projects, concentrating expertise and always keeping clinical impact in mind, we contribute to translating basic research into actual medical progress.

Thank you to the scientists, physicians, patrons, partners and friends who make this mission a reality.

Let us continue to push the boundaries for the future of medicine.